Several other equities analysts have also commented on the stock. Shore Capital restated a hold rating on shares of Astrazeneca PLC in a report on Wednesday, July 27th. Citigroup Inc. restated a buy rating on shares of Astrazeneca PLC in a report on Friday, September 23rd. Berenberg Bank restated a buy rating on shares of Astrazeneca PLC in a report on Sunday, September 11th. Beaufort Securities restated a hold rating on shares of Astrazeneca PLC in a report on Friday, August 26th. Finally, Cantor Fitzgerald reaffirmed a buy rating on shares of Astrazeneca PLC in a research note on Thursday, July 28th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $37.44.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 32.26 on Tuesday. The firm has a market capitalization of $81.62 billion, a P/E ratio of 36.87 and a beta of 0.75. Astrazeneca PLC has a 1-year low of $26.97 and a 1-year high of $35.04. The stock’s 50 day moving average is $33.27 and its 200 day moving average is $30.76.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The firm had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. During the same period in the prior year, the business posted $1.21 EPS. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. Equities analysts predict that Astrazeneca PLC will post $2.97 earnings per share for the current year.
The business also recently announced a dividend, which was paid on Monday, September 12th. Investors of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is 78.29%.
A number of hedge funds have recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Astrazeneca PLC during the fourth quarter worth $10,211,000. TIAA CREF Investment Management LLC boosted its stake in shares of Astrazeneca PLC by 45.2% in the first quarter. TIAA CREF Investment Management LLC now owns 398,366 shares of the company’s stock worth $11,218,000 after buying an additional 124,066 shares in the last quarter. Teachers Advisors Inc. boosted its stake in shares of Astrazeneca PLC by 595.6% in the first quarter. Teachers Advisors Inc. now owns 510,989 shares of the company’s stock worth $14,389,000 after buying an additional 437,531 shares in the last quarter. Mckinley Capital Management LLC Delaware boosted its stake in shares of Astrazeneca PLC by 5.6% in the first quarter. Mckinley Capital Management LLC Delaware now owns 64,856 shares of the company’s stock worth $1,826,000 after buying an additional 3,449 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Astrazeneca PLC by 89.8% in the first quarter. Franklin Resources Inc. now owns 2,026,200 shares of the company’s stock worth $57,058,000 after buying an additional 958,821 shares in the last quarter. Hedge funds and other institutional investors own 11.39% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.